Increasing Clinical Trial Diversity With Federal Incentives and Regulations

Recent U.S. legislation requires clinical trial sponsors to submit a diversity action plan for pivotal studies of new drugs. Still, Thomas J. Hwang, MD, and a colleague propose a combination of federal incentives and regulations to advance clinical trial equity and resolve gaps in participant representation.
Read More...